Literature DB >> 32640022

The ethical case for global measles eradication-justice and the Rule of Rescue.

David N Durrheim1, Jon K Andrus2.   

Abstract

Measles causes a substantial disease burden for all countries, while mortality is greatest in underserved, marginalized populations. Global measles eradication is feasible and the strategies critically rely upon well-functioning national immunisation programs and surveillance systems. All six regions of the World Health Organisation have adopted measles elimination targets. The Rule of Rescue and the principle of justice leave no ethical place for health programs, governments, global public health bodies or donors to hide if they impede efforts to eradicate measles globally by not taking all necessary actions to establish a global eradication target and committing the resources essential to achieve this goal.
© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

Entities:  

Keywords:  eradication; ethics; justice; measles; rescue

Mesh:

Substances:

Year:  2020        PMID: 32640022      PMCID: PMC7443714          DOI: 10.1093/inthealth/ihaa038

Source DB:  PubMed          Journal:  Int Health        ISSN: 1876-3405            Impact factor:   2.473


Introduction

Measles is estimated to have claimed the lives of >142 000 people, mainly young children, in 2018; a staggering 18 000 more deaths than in 2017.[1] The global resurgence in measles cases that began in 2016 continues unabated, with more reported cases in 2019 than the total for 2017 and 2018.[2] The region of the Americas, due to reestablishment of endemic measles circulation in Venezuela and Brazil, and countries in Europe (Albania, Czech Republic, Greece and the UK) and the Western Pacific region (Mongolia) that had previously been verified to have interrupted measles transmission have lost their verification status.[3-5] As a result, the argument has been made that the current global measles situation meets the criteria of a Public Health Emergency of International Concern (PHEIC), but the World Health Organization (WHO) has not declared a PHEIC.[6] Viewed through the Rule of Rescue lens and when weighed on the scales of justice, this performance by humankind is found to be ethically wanting.

Is measles eradication possible?

‘Measles can and should be eradicated’ was the conclusion of the Strategic Advisory Group of Experts (SAGE) Working Group on Immunization to the WHO following an exhaustive review of biological, technical, economic and programmatic evidence.[7] Furthermore, SAGE recommended that a goal for measles eradication (reduction of global measles incidence to zero as a result of deliberate efforts) should be established. This belief and commitment was reflected in the Global Vaccine Action Plan, which was endorsed by the World Health Assembly in 2012, setting the goal for measles elimination in five regions by 2020.[8] Regional enthusiasm exceeded this target, with each of the six regions committing to eliminating endemic measles on or before 2020. Measles can be eradicated; the Americas achieved zero endemic measles cases in November 2002.[9] To that end, all regions have committed to achieving the public health goal of measles elimination, yet an unacceptable number of children died of this totally preventable disease in 2018. The worldwide epidemiological situation continues to deteriorate. Measles resurgence reflects stagnating global coverage with measles-containing vaccine (MCV), which has plateaued for the past decade at approximately 85%, about 10% lower than necessary to prevent outbreaks and cease transmission. Fortunately, strengthening the essential immunisation program is, and should be, the foundation for eradicating measles. The key to sustainable measles elimination is investing in the primary health structure at the point of service delivery, strengthening surveillance and ensuring the necessary community engagement and political commitment to reach every child with MCV and other integrated immunisation and primary healthcare services. The coronavirus disease 2019 pandemic is having a negative impact on routine immunization coverage in many countries and this burden is likely to fall more heavily on developing countries. Given this negative impact, we should expect to see expanded measles outbreaks in the near future. If a safe and effective pandemic vaccine becomes available, it will be crucial to piggyback routine immunization catch-up onto pandemic outreach immunization activities in an attempt to close the inequitable immunization gap between stronger and weaker health systems, while also addressing an inevitable measles resurgence.

Ethical arguments for and against measles eradication

There is little doubt that eradication will take a major coordinated effort, but the benefits will extend well beyond extinction of the virus. To achieve the phenomenal vaccine coverage required to eradicate measles will require that health systems perform well, reach every community and protect almost every child. Thus previous ethical justification for achieving measles eradication has focused predominantly on equity.[10] The occurrence of measles highlights inequity in health service provision, graphically illustrated by an analysis of 123 million neonatal, infant and child deaths between 2000 and 2017.[11] The obvious clustering of deaths by low socio-economic status at a subnational scale in 99 countries mirrors the occurrence of measles. The children who are at greatest risk of severe disease have poor nutrition, co-infections and limited access to healthcare. Reaching them with immunisation will have a real effect on health inequities. As the burden of premature deaths falls disproportionately on the very young, if the global community does not respond with solidarity and commitment, the young will continue to be swindled of their ‘normal’ healthy lifespan.[12] Because measles elimination relies so heavily on essential immunization services, reaching these children will also give them the benefit of other lifesaving vaccines. The goal of measles eradication has been ethically questioned, with a primary concern being the attendant cost and reliability of achieving eradication. It has been argued that after achieving eradication, prophylaxis and vigilance would be replaced with indifference and trust.[13] With the dual threats of bioterrorism in immune-naïve populations and the possibility of virus escape from a laboratory or undetected virus in marginalised communities, it is contended that embarking on measles eradication is unethical. The principle of beneficence, and more particularly the rule of rescue, demands that those who are able, in this case governments and international donors, rescue identifiable individuals facing avoidable death, if personal sacrifice is not excessive.[14] An analogy may be useful. We are fortunate to be surviving in a life boat. If we reach out to save a drowning victim and hoist him/her on board, will we capsize the lifeboat and risk our own lives? Given the compelling scientific evidence of the feasibility of eradication and the preventable death toll exacted annually by measles, the rule of rescue is a potent ethical sabre for compelling accelerated global action. Although the Rule of Rescue has been criticised as benefitting a few at a cost to many, this utilitarian counterargument appears flawed, given the cost-effectiveness of measles vaccination and the return on investment of eliminating measles, and concurrently rubella and congenital rubella syndrome (CRS) through using a combination vaccine. As an aside, the experience in the Americas demonstrated that the combined vaccine approach provides a side benefit of CRS elimination, a result that has been substantially cost-saving and humanitarian.[15,16] The colossal net economic gains of eradicating measles infection, primarily through direct treatment and outbreak response costs saved (>US$2 billion per year) and disability-adjusted life year (DALY) losses prevented (>15 million DALYs per year valued at >US$63 billion), could provide much needed investment in other public health programmes.[17] Measles eradication could be further defended from a utilitarian perspective on the grounds that the commitment to rescuing the most vulnerable will increase societal well-being by reinforcing people's belief that they live in a community that places great value upon life and fairness.[18]

When it comes to a measles eradication goal, is there any ethical place to hide?

Beneficence is influenced by the consequences of doing nothing, the feasibility of preventing serious consequences and the scale of sacrifice. On all three counts the Rule of Rescue compels us to make every reasonable effort to eradicate measles. Recently the United Nations High Commissioner for Human Rights, Michelle Bachelet, a paediatrician and former president of Chile, penned an insightful reflection on health inequities in childhood, ‘Data on child deaths are a call for justice’.[19] She argued that hard data must be followed by action across the whole spectrum of government and society. At the 70th World Health Assembly (WHA) in 2017, the director-general was requested to report through the Executive Board to the 73rd WHA in 2020 ‘on the epidemiological aspects and feasibility of, and potential resource requirements for, measles and rubella eradication, taking into account the assessment of the SAGE on immunization’.[20] Unfortunately the question of setting a measles eradication goal was not debated at the WHA in Geneva in May 2020 because SAGE concluded in their feasibility assessment just prior to the WHA that: ‘Given the current global context, achieving measles eradication is not realistic without significant further effort. There is an urgent need for all countries and regions to accelerate progress towards achieving and maintaining measles and rubella elimination goals’.[21] Governments and international health agencies do not have any escape from the ethical compulsion to accelerate the achievement of this goal without any further delay.
  12 in total

1.  Is disease eradication ethical?

Authors:  Arthur L Caplan
Journal:  Lancet       Date:  2009-06-27       Impact factor: 79.321

2.  Proceedings of the Global Technical Consultation to assess the feasibility of measles eradication, 28-30 July 2010.

Authors: 
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

Review 3.  Intergenerational equity: an exploration of the 'fair innings' argument.

Authors:  A Williams
Journal:  Health Econ       Date:  1997 Mar-Apr       Impact factor: 3.046

4.  Is the global measles resurgence a "public health emergency of international concern"?

Authors:  David N Durrheim; Natasha S Crowcroft; Lucille H Blumberg
Journal:  Int J Infect Dis       Date:  2019-05-02       Impact factor: 3.623

5.  The problem with rescue medicine.

Authors:  Nancy S Jecker
Journal:  J Med Philos       Date:  2012-12-23

Review 6.  Measles and rubella eradication in the Americas.

Authors:  Jon Kim Andrus; Ciro A de Quadros; Carlos Castillo Solórzano; Mirta Roses Periago; D A Henderson
Journal:  Vaccine       Date:  2011-12-18       Impact factor: 3.641

7.  Data on child deaths are a call for justice.

Authors:  Michelle Bachelet
Journal:  Nature       Date:  2019-10       Impact factor: 49.962

Review 8.  Systematic Review of Health Economic Analyses of Measles and Rubella Immunization Interventions.

Authors:  Kimberly M Thompson; Cassie L Odahowski
Journal:  Risk Anal       Date:  2014-12-24       Impact factor: 4.000

9.  Progress Toward Measles Elimination - Western Pacific Region, 2013-2017.

Authors:  José E Hagan; Jennifer L Kriss; Yoshihiro Takashima; Kayla Mae L Mariano; Roberta Pastore; Varja Grabovac; Alya J Dabbagh; James L Goodson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-05-04       Impact factor: 17.586

10.  Mapping 123 million neonatal, infant and child deaths between 2000 and 2017.

Authors:  Roy Burstein; Nathaniel J Henry; Michael L Collison; Laurie B Marczak; Amber Sligar; Stefanie Watson; Neal Marquez; Mahdieh Abbasalizad-Farhangi; Masoumeh Abbasi; Foad Abd-Allah; Amir Abdoli; Mohammad Abdollahi; Ibrahim Abdollahpour; Rizwan Suliankatchi Abdulkader; Michael R M Abrigo; Dilaram Acharya; Oladimeji M Adebayo; Victor Adekanmbi; Davoud Adham; Mahdi Afshari; Mohammad Aghaali; Keivan Ahmadi; Mehdi Ahmadi; Ehsan Ahmadpour; Rushdia Ahmed; Chalachew Genet Akal; Joshua O Akinyemi; Fares Alahdab; Noore Alam; Genet Melak Alamene; Kefyalew Addis Alene; Mehran Alijanzadeh; Cyrus Alinia; Vahid Alipour; Syed Mohamed Aljunid; Mohammed J Almalki; Hesham M Al-Mekhlafi; Khalid Altirkawi; Nelson Alvis-Guzman; Adeladza Kofi Amegah; Saeed Amini; Arianna Maever Loreche Amit; Zohreh Anbari; Sofia Androudi; Mina Anjomshoa; Fereshteh Ansari; Carl Abelardo T Antonio; Jalal Arabloo; Zohreh Arefi; Olatunde Aremu; Bahram Armoon; Amit Arora; Al Artaman; Anvar Asadi; Mehran Asadi-Aliabadi; Amir Ashraf-Ganjouei; Reza Assadi; Bahar Ataeinia; Sachin R Atre; Beatriz Paulina Ayala Quintanilla; Martin Amogre Ayanore; Samad Azari; Ebrahim Babaee; Arefeh Babazadeh; Alaa Badawi; Soghra Bagheri; Mojtaba Bagherzadeh; Nafiseh Baheiraei; Abbas Balouchi; Aleksandra Barac; Quique Bassat; Bernhard T Baune; Mohsen Bayati; Neeraj Bedi; Ettore Beghi; Masoud Behzadifar; Meysam Behzadifar; Yared Belete Belay; Brent Bell; Michelle L Bell; Dessalegn Ajema Berbada; Robert S Bernstein; Natalia V Bhattacharjee; Suraj Bhattarai; Zulfiqar A Bhutta; Ali Bijani; Somayeh Bohlouli; Nicholas J K Breitborde; Gabrielle Britton; Annie J Browne; Sharath Burugina Nagaraja; Reinhard Busse; Zahid A Butt; Josip Car; Rosario Cárdenas; Carlos A Castañeda-Orjuela; Ester Cerin; Wagaye Fentahun Chanie; Pranab Chatterjee; Dinh-Toi Chu; Cyrus Cooper; Vera M Costa; Koustuv Dalal; Lalit Dandona; Rakhi Dandona; Farah Daoud; Ahmad Daryani; Rajat Das Gupta; Ian Davis; Nicole Davis Weaver; Dragos Virgil Davitoiu; Jan-Walter De Neve; Feleke Mekonnen Demeke; Gebre Teklemariam Demoz; Kebede Deribe; Rupak Desai; Aniruddha Deshpande; Hanna Demelash Desyibelew; Sagnik Dey; Samath Dhamminda Dharmaratne; Meghnath Dhimal; Daniel Diaz; Leila Doshmangir; Andre R Duraes; Laura Dwyer-Lindgren; Lucas Earl; Roya Ebrahimi; Soheil Ebrahimpour; Andem Effiong; Aziz Eftekhari; Elham Ehsani-Chimeh; Iman El Sayed; Maysaa El Sayed Zaki; Maha El Tantawi; Ziad El-Khatib; Mohammad Hassan Emamian; Shymaa Enany; Sharareh Eskandarieh; Oghenowede Eyawo; Maha Ezalarab; Mahbobeh Faramarzi; Mohammad Fareed; Roghiyeh Faridnia; Andre Faro; Ali Akbar Fazaeli; Mehdi Fazlzadeh; Netsanet Fentahun; Seyed-Mohammad Fereshtehnejad; João C Fernandes; Irina Filip; Florian Fischer; Nataliya A Foigt; Masoud Foroutan; Joel Msafiri Francis; Takeshi Fukumoto; Nancy Fullman; Silvano Gallus; Destallem Gebremedhin Gebre; Tsegaye Tewelde Gebrehiwot; Gebreamlak Gebremedhn Gebremeskel; Bradford D Gessner; Birhanu Geta; Peter W Gething; Reza Ghadimi; Keyghobad Ghadiri; Mahsa Ghajarzadeh; Ahmad Ghashghaee; Paramjit Singh Gill; Tiffany K Gill; Nick Golding; Nelson G M Gomes; Philimon N Gona; Sameer Vali Gopalani; Giuseppe Gorini; Bárbara Niegia Garcia Goulart; Nicholas Graetz; Felix Greaves; Manfred S Green; Yuming Guo; Arvin Haj-Mirzaian; Arya Haj-Mirzaian; Brian James Hall; Samer Hamidi; Hamidreza Haririan; Josep Maria Haro; Milad Hasankhani; Edris Hasanpoor; Amir Hasanzadeh; Hadi Hassankhani; Hamid Yimam Hassen; Mohamed I Hegazy; Delia Hendrie; Fatemeh Heydarpour; Thomas R Hird; Chi Linh Hoang; Gillian Hollerich; Enayatollah Homaie Rad; Mojtaba Hoseini-Ghahfarokhi; Naznin Hossain; Mostafa Hosseini; Mehdi Hosseinzadeh; Mihaela Hostiuc; Sorin Hostiuc; Mowafa Househ; Mohamed Hsairi; Olayinka Stephen Ilesanmi; Mohammad Hasan Imani-Nasab; Usman Iqbal; Seyed Sina Naghibi Irvani; Nazrul Islam; Sheikh Mohammed Shariful Islam; Mikk Jürisson; Nader Jafari Balalami; Amir Jalali; Javad Javidnia; Achala Upendra Jayatilleke; Ensiyeh Jenabi; John S Ji; Yash B Jobanputra; Kimberly Johnson; Jost B Jonas; Zahra Jorjoran Shushtari; Jacek Jerzy Jozwiak; Ali Kabir; Amaha Kahsay; Hamed Kalani; Rohollah Kalhor; Manoochehr Karami; Surendra Karki; Amir Kasaeian; Nicholas J Kassebaum; Peter Njenga Keiyoro; Grant Rodgers Kemp; Roghayeh Khabiri; Yousef Saleh Khader; Morteza Abdullatif Khafaie; Ejaz Ahmad Khan; Junaid Khan; Muhammad Shahzeb Khan; Young-Ho Khang; Khaled Khatab; Amir Khater; Mona M Khater; Alireza Khatony; Mohammad Khazaei; Salman Khazaei; Maryam Khazaei-Pool; Jagdish Khubchandani; Neda Kianipour; Yun Jin Kim; Ruth W Kimokoti; Damaris K Kinyoki; Adnan Kisa; Sezer Kisa; Tufa Kolola; Soewarta Kosen; Parvaiz A Koul; Ai Koyanagi; Moritz U G Kraemer; Kewal Krishan; Kris J Krohn; Nuworza Kugbey; G Anil Kumar; Manasi Kumar; Pushpendra Kumar; Desmond Kuupiel; Ben Lacey; Sheetal D Lad; Faris Hasan Lami; Anders O Larsson; Paul H Lee; Mostafa Leili; Aubrey J Levine; Shanshan Li; Lee-Ling Lim; Stefan Listl; Joshua Longbottom; Jaifred Christian F Lopez; Stefan Lorkowski; Sameh Magdeldin; Hassan Magdy Abd El Razek; Muhammed Magdy Abd El Razek; Azeem Majeed; Afshin Maleki; Reza Malekzadeh; Deborah Carvalho Malta; Abdullah A Mamun; Navid Manafi; Ana-Laura Manda; Morteza Mansourian; Francisco Rogerlândio Martins-Melo; Anthony Masaka; Benjamin Ballard Massenburg; Pallab K Maulik; Benjamin K Mayala; Mohsen Mazidi; Martin McKee; Ravi Mehrotra; Kala M Mehta; Gebrekiros Gebremichael Meles; Walter Mendoza; Ritesh G Menezes; Atte Meretoja; Tuomo J Meretoja; Tomislav Mestrovic; Ted R Miller; Molly K Miller-Petrie; Edward J Mills; George J Milne; G K Mini; Seyed Mostafa Mir; Hamed Mirjalali; Erkin M Mirrakhimov; Efat Mohamadi; Dara K Mohammad; Aso Mohammad Darwesh; Naser Mohammad Gholi Mezerji; Ammas Siraj Mohammed; Shafiu Mohammed; Ali H Mokdad; Mariam Molokhia; Lorenzo Monasta; Yoshan Moodley; Mahmood Moosazadeh; Ghobad Moradi; Masoud Moradi; Yousef Moradi; Maziar Moradi-Lakeh; Mehdi Moradinazar; Paula Moraga; Lidia Morawska; Abbas Mosapour; Seyyed Meysam Mousavi; Ulrich Otto Mueller; Atalay Goshu Muluneh; Ghulam Mustafa; Behnam Nabavizadeh; Mehdi Naderi; Ahamarshan Jayaraman Nagarajan; Azin Nahvijou; Farid Najafi; Vinay Nangia; Duduzile Edith Ndwandwe; Nahid Neamati; Ionut Negoi; Ruxandra Irina Negoi; Josephine W Ngunjiri; Huong Lan Thi Nguyen; Long Hoang Nguyen; Son Hoang Nguyen; Katie R Nielsen; Dina Nur Anggraini Ningrum; Yirga Legesse Nirayo; Molly R Nixon; Chukwudi A Nnaji; Marzieh Nojomi; Mehdi Noroozi; Shirin Nosratnejad; Jean Jacques Noubiap; Soraya Nouraei Motlagh; Richard Ofori-Asenso; Felix Akpojene Ogbo; Kelechi E Oladimeji; Andrew T Olagunju; Meysam Olfatifar; Solomon Olum; Bolajoko Olubukunola Olusanya; Mojisola Morenike Oluwasanu; Obinna E Onwujekwe; Eyal Oren; Doris D V Ortega-Altamirano; Alberto Ortiz; Osayomwanbo Osarenotor; Frank B Osei; Aaron E Osgood-Zimmerman; Stanislav S Otstavnov; Mayowa Ojo Owolabi; Mahesh P A; Abdol Sattar Pagheh; Smita Pakhale; Songhomitra Panda-Jonas; Animika Pandey; Eun-Kee Park; Hadi Parsian; Tahereh Pashaei; Sangram Kishor Patel; Veincent Christian Filipino Pepito; Alexandre Pereira; Samantha Perkins; Brandon V Pickering; Thomas Pilgrim; Majid Pirestani; Bakhtiar Piroozi; Meghdad Pirsaheb; Oleguer Plana-Ripoll; Hadi Pourjafar; Parul Puri; Mostafa Qorbani; Hedley Quintana; Mohammad Rabiee; Navid Rabiee; Amir Radfar; Alireza Rafiei; Fakher Rahim; Zohreh Rahimi; Vafa Rahimi-Movaghar; Shadi Rahimzadeh; Fatemeh Rajati; Sree Bhushan Raju; Azra Ramezankhani; Chhabi Lal Ranabhat; Davide Rasella; Vahid Rashedi; Lal Rawal; Robert C Reiner; Andre M N Renzaho; Satar Rezaei; Aziz Rezapour; Seyed Mohammad Riahi; Ana Isabel Ribeiro; Leonardo Roever; Elias Merdassa Roro; Max Roser; Gholamreza Roshandel; Daem Roshani; Ali Rostami; Enrico Rubagotti; Salvatore Rubino; Siamak Sabour; Nafis Sadat; Ehsan Sadeghi; Reza Saeedi; Yahya Safari; Roya Safari-Faramani; Mahdi Safdarian; Amirhossein Sahebkar; Mohammad Reza Salahshoor; Nasir Salam; Payman Salamati; Farkhonde Salehi; Saleh Salehi Zahabi; Yahya Salimi; Hamideh Salimzadeh; Joshua A Salomon; Evanson Zondani Sambala; Abdallah M Samy; Milena M Santric Milicevic; Bruno Piassi Sao Jose; Sivan Yegnanarayana Iyer Saraswathy; Rodrigo Sarmiento-Suárez; Benn Sartorius; Brijesh Sathian; Sonia Saxena; Alyssa N Sbarra; Lauren E Schaeffer; David C Schwebel; Sadaf G Sepanlou; Seyedmojtaba Seyedmousavi; Faramarz Shaahmadi; Masood Ali Shaikh; Mehran Shams-Beyranvand; Amir Shamshirian; Morteza Shamsizadeh; Kiomars Sharafi; Mehdi Sharif; Mahdi Sharif-Alhoseini; Hamid Sharifi; Jayendra Sharma; Rajesh Sharma; Aziz Sheikh; Chloe Shields; Mika Shigematsu; Rahman Shiri; Ivy Shiue; Kerem Shuval; Tariq J Siddiqi; João Pedro Silva; Jasvinder A Singh; Dhirendra Narain Sinha; Malede Mequanent Sisay; Solomon Sisay; Karen Sliwa; David L Smith; Ranjani Somayaji; Moslem Soofi; Joan B Soriano; Chandrashekhar T Sreeramareddy; Agus Sudaryanto; Mu'awiyyah Babale Sufiyan; Bryan L Sykes; P N Sylaja; Rafael Tabarés-Seisdedos; Karen M Tabb; Takahiro Tabuchi; Nuno Taveira; Mohamad-Hani Temsah; Abdullah Sulieman Terkawi; Zemenu Tadesse Tessema; Kavumpurathu Raman Thankappan; Sathish Thirunavukkarasu; Quyen G To; Marcos Roberto Tovani-Palone; Bach Xuan Tran; Khanh Bao Tran; Irfan Ullah; Muhammad Shariq Usman; Olalekan A Uthman; Amir Vahedian-Azimi; Pascual R Valdez; Job F M van Boven; Tommi Juhani Vasankari; Yasser Vasseghian; Yousef Veisani; Narayanaswamy Venketasubramanian; Francesco S Violante; Sergey Konstantinovitch Vladimirov; Vasily Vlassov; Theo Vos; Giang Thu Vu; Isidora S Vujcic; Yasir Waheed; Jon Wakefield; Haidong Wang; Yafeng Wang; Yuan-Pang Wang; Joseph L Ward; Robert G Weintraub; Kidu Gidey Weldegwergs; Girmay Teklay Weldesamuel; Ronny Westerman; Charles Shey Wiysonge; Dawit Zewdu Wondafrash; Lauren Woyczynski; Ai-Min Wu; Gelin Xu; Abbas Yadegar; Tomohide Yamada; Vahid Yazdi-Feyzabadi; Christopher Sabo Yilgwan; Paul Yip; Naohiro Yonemoto; Javad Yoosefi Lebni; Mustafa Z Younis; Mahmoud Yousefifard; Hebat-Allah Salah A Yousof; Chuanhua Yu; Hasan Yusefzadeh; Erfan Zabeh; Telma Zahirian Moghadam; Sojib Bin Zaman; Mohammad Zamani; Hamed Zandian; Alireza Zangeneh; Taddese Alemu Zerfu; Yunquan Zhang; Arash Ziapour; Sanjay Zodpey; Christopher J L Murray; Simon I Hay
Journal:  Nature       Date:  2019-10-16       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.